

1 **Washington Vaccine Association**
2 **Board of Directors Meeting**
3 **February 22; 2:00-4:00 p.m. (PT)**
4

5 **I. Attendance.** This meeting was conducted virtually. Participating in all or part of the meeting were the following
6 individuals:

7		
8	<u>Directors</u>	23 Cheri Cagle, Stakeholder Liaison
9	John Dunn, MPH, MD, Kaiser Permanente, <i>Chair</i>	24
10	Beth Harvey, MD, South Sound Pediatrics, <i>Vice Chair</i>	25 <u>Helms & Company, Inc.</u>
11	Ed Marcuse, MD, MPH, FPIDS, University of Washington, <i>Secretary</i>	26 Patrick Miller, MPH, WVA, Administrative Director
12	John Sobek, MBA, MD, Regence Blue Shield, <i>Treasurer</i>	27 Ashley Ithal, MPH, WVA, Program Support
13	Steven Caplow, Esq., DWT LLP	28 Leslie Walker, CPA, Mason+Rich, PA
14	Helen Chea, MD, Molina	29
15	Kara Manley, United Healthcare	30 <u>Others</u>
16	Chad Murphy, BS, PharmD, Premera	31 Anne Redman, Esq., Perkins Coie
17	Michele Roberts, Washington Department of Health	32 Janel Jorgenson, Washington Department of Health
18	Pamela Sheffield, MD, Aetna	33 Jamilia Sherls-Jones, Washington Department of Health
19		34 Breeilyn Young, GSK
20		35 Rick Hourigan, MD, Cigna
21	<u>WVA</u>	36 Lisa Templeton, ICWA
22	Julia Walter Zell, MA., Esq., Executive Director	37 Bob Runnells, ICWA
23		

38
39 **II. Summary of Actions Taken and/or Recommended**
40

41 Actions Taken (votes adopted)

- 42 i. To approve the minutes of the November 2, 2023, Board Meeting.
43 ii. Vote to confirm Steven Caplow as a Board Member.
44 iii. Vote to approve Steven Caplow as a Finance Committee Member.
45

46 **III. Minutes**
47

48 Welcome and Introductions

49 Dr. Dunn called the meeting to order at 2:02 p.m. Ms. Zell provided a notice of recording for the purposes of the
50 meeting minutes. The recording will be deleted once the meeting minutes are approved.
51

52 Consent Calendar

53 Dr. Dunn asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously
54

55 **VOTED: To approve the minutes of the November 2, 2023, Board Meeting.**
56

57 Ms. Zell informed the Board that Mr. Farber resigned after serving over a decade. She welcomed Mr. Caplow as a
58 replacement for Mr. Farber and invited him to introduce himself. Ms. Zell reported that Ms. Roberts provided an
59 appointment letter for Mr. Caplow from the Secretary. Dr. Dunn asked for a motion to confirm Mr. Caplow as a Board
60 Member. Upon motion duly made and seconded, it was unanimously
61

62 **VOTED: Vote to confirm Steven Caplow as a Board Member.**
63

64 Dr. Dunn asked for a motion to approve Mr. Caplow as a Finance Committee Member. Upon motion duly made and
65 seconded, it was unanimously
66

67 **VOTED: Vote to approve Steven Caplow as a Finance Committee Member.**
68
69
70
71

72 **IV. Financial Updates**

73

74 Unaudited Financial Statements

75 Mr. Miller provided an overview of the unaudited financial statements through January 31, 2024. Mr. Miller reported
76 that cash balances for the last few months have ended the month with less than the beginning, as expected, largely due
77 to the addition of COVID-19 vaccines and nirsevimab last fall. From a cash perspective on the balance sheet, the
78 WVA has \$5.7M in cash equivalents and \$17.4M in its investment portfolio. WVA's administrative expenses are
79 \$98K ahead of budget.

80

81 FY2025 Vaccine Grid Update

82 Ms. Zell introduced the topic of the FY2025 Vaccine Grid model. She reminded the group that an increase for FY2025
83 is expected due to the addition of new immunizations and vaccine inflation. Additionally, Ms. Zell noted that the Grid
84 increase would assist with rebuilding the reserves that were used for the purchase of nirsevimab, and this would occur
85 over a three-year period. Mr. Miller reviewed the 2024-25 timeline for the administrative budget and vaccine grid
86 development. He reviewed the current set of draft assumptions for the model. He stated that the first view of the model
87 will be shared with the Finance Committee in two weeks.

88

89 Dr. Sobeck announced that he has resigned from his position at Cambia and thus will need to resign from the Board
90 and Finance Committee following the Finance Committee meeting in March. Several Board Members thanked Dr.
91 Sobeck for his many years of commitment to the WVA and offered their desire to have him return in the future.

92

93 **V. WA Department of Health (DOH) Updates**

94

95 Ms. Roberts stated that the legislation for the statutory change has passed the House and the Senate and will be sent
96 to Governor Inslee for signature. Dr. Dunn thanked the DOH for their continued partnership and for specifically
97 partnering on this effort to provide immunizations for children in Washington.

98

99 Ms. Sherls-Jones noted that the DOH is tracking SB1695 which would grant the Secretary of Health the ability to
100 issue standing orders, especially in the event of public health emergencies.

101

102 Ms. Sherls-Jones noted that the DOH has a limited amount of nirsevimab available for ordering and that ordering will
103 continue until supply is depleted. The has been encouraging providers to post unused nirsevimab dosages to the
104 vaccine advertisement tool in the IIS to reallocate supply. Unused product can be kept through next season if stored
105 properly as expiration dates extend into 2025. Ms. Sherls-Jones reported that the CDC will use an allocation
106 distribution of nirsevimab this fall to ensure steady supply albeit the CDC does not anticipate supply chain shortages.

107

108 Ms. Sherls-Jones reported that the DOH has completed their influenza pre-book order for the upcoming flu season.
109 The DOH reduced their order by 200,000 doses due to decreased demand seen in the past three years. The DOH
110 reported an approximate 30% coverage rate for influenza vaccination this season with about 27% of children below
111 18 having received at least one dose of influenza vaccine.

112

113 Ms. Sherls-Jones noted that the Penbraya™ meningococcal vaccine will be available in spring 2024, however, the
114 DOH is being told that provider demand is low.

115

116 Ms. Sherls-Jones reported that at the close of CY 2023 over 1.9 million vaccine doses, excluding influenza and
117 COVID, were administered to children, ages 0 to 18 years, in 2023 which was a 2.15% increase from CY 2022.

118

119 **VI. ED/AD Updates**

120

121 Inpatient Hospital Billing

122 Ms. Zell provided an update on the inpatient hospital billing workgroup progress. The WVA statutory change
123 alleviates timeline concerns in onboarding the hospitals by July 2024. Ms. Zell noted that an inpatient hospital billing
124 guide was approved by the workgroup, published on the WVA website, and shared with the hospitals. She noted that
125 in addition to the providers, there will be an effort needed by the payers for updating their systems to support these
126 changes. Ms. Zell noted that there will be beta testing with several hospitals and payers prior to July 2024.

127

128 Provider Engagement

129 Ms. Zell thanked Ms. Cagle for her provider engagement work to date. Ms. Cagle reported that her work included
130 provider outreach for billing system set up issues. Mr. Miller said the WVA relied on the payers to provide information
131 on which providers needed to update their systems.

132

133 **VII. Public Comments**

134

135 Ms. Young stated that her team was soliciting provider feedback regarding the upcoming influenza changes. Mr.
136 Hourigan indicated he had no comments. Ms. Templeton indicated she had no comments. Mr. Runnells provided an
137 updated weblink for the WVA website.

138

139 Dr. Dunn thanked the members of the public for their comments and requested that the committee move into Executive
140 Session. Ms. Roberts requested that Ms. Sherls-Jones and Ms. Jorgenson remain. Mr. Miller requested Ms. Ithal
141 remain.

142

143 **VIII. Executive Session - Confidential.**

144

145 **IX. Closing**

146

147 With no further business before the Board, Dr. Dunn closed the meeting at 4:00 p.m.